July 10, 2024 02:34 PM EDT

Thermo Fisher closes $3.1B Olink acquisition after UK antitrust review is cleared

Jared Whitlock

Features Editor

Life sciences giant Thermo Fisher on Wednesday closed its $3.1 billion deal for Olink, adding protein analysis to its drug discovery tools in a move …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Thermo Fisher closes $3.1B Olink acquisition after UK antitrust review is cleared

Jared Whitlock

Features Editor

Sign up to read this article for free.

Secretive Treeline Biosciences discloses $421M financing in filing

BenevolentAI CEO is out after less than a year on the job

FDA approves AbbVie's 24-hour Parkinson's infusion therapy after two CRLs

House’s prominent China critic Jim McGovern leads opposition to Biosecure Act: ‘I would prefer to go back to the ...

Sage shakes up senior management, slashes pipeline, sheds 33% of staff

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies

Ther­mo Fish­er clos­es $3.1B Olink ac­qui­si­tion af­ter UK an­titrust re­view is cleared

Jared Whitlock

Features Editor

Sign up to read this article for free.

Se­cre­tive Tree­line Bio­sciences dis­clos­es $421M fi­nanc­ing in fil­ing

Benev­o­len­tAI CEO is out af­ter less than a year on the job

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

House’s promi­nent Chi­na crit­ic Jim Mc­Gov­ern leads op­po­si­tion to Biose­cure Act: ‘I would pre­fer to go back to the ...

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

Thermo Fisher closes $3.1B Olink acquisition after UK antitrust review is cleared

Secretive Treeline Biosciences discloses $421M financing in filing

BenevolentAI CEO is out after less than a year on the job

FDA approves AbbVie's 24-hour Parkinson's infusion therapy after two CRLs

House’s prominent China critic Jim McGovern leads opposition to Biosecure Act: ‘I would prefer to go back to the ...

Sage shakes up senior management, slashes pipeline, sheds 33% of staff

Join the GenScript Biotech Global Forum: Unlocking Innovations in Cell and Gene Therapies